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Background: Age-adjusted lymphoma incidence rates continue to rise in France since the early 80’s, although rates
have slowed since 2010 and vary across subtypes. Recent improvements in patient survival in major lymphoma
subtypes at population level raise new questions about patient outcomes (i.e. quality of life, long-term sequelae).
Epidemiological studies have investigated factors related to lymphoma risk, but few have addressed the extent to
which socioeconomic status, social institutional context (i.e. healthcare system), social relationships, environmental
context (exposures), individual behaviours (lifestyle) or genetic determinants influence lymphoma outcomes,
especially in the general population. Moreover, the knowledge of the disease behaviour mainly obtained from
clinical trials data is partly biased because of patient selection.
Methods: The REALYSA (“REal world dAta in LYmphoma and Survival in Adults”) study is a real-life multicentric
cohort set up in French areas covered by population-based cancer registries to study the prognostic value of
epidemiological, clinical and biological factors with a prospective 9-year follow-up. We aim to include 6000 patients
over 4 to 5 years. Adult patients without lymphoma history and newly diagnosed with one of the following 7
lymphoma subtypes (diffuse large B-cell, follicular, marginal zone, mantle cell, Burkitt, Hodgkin, mature T-cell) are
invited to participate during a medical consultation with their hematologist. Exclusion criteria are: having already
received anti-lymphoma treatment (except pre-phase) and having a documented HIV infection. Patients are treated
according to the standard practice in their center. Clinical data, including treatment received, are extracted from
patients’ medical records. Patients’ risk factors exposures and other epidemiological data are obtained at baseline
by filling out a questionnaire during an interview led by a clinical research assistant. Biological samples are collected
at baseline and during treatment. A virtual tumor biobank is constituted for baseline tumor samples. Follow-up
data, both clinical and epidemiological, are collected every 6 months in the first 3 years and every year thereafter.
Discussion: This cohort constitutes an innovative platform for clinical, biological, epidemiological and socio-
economic research projects and provides an opportunity to improve knowledge on factors associated to outcome
of lymphoma patients in real life.
Trial registration: 2018-A01332–53, ClinicalTrials.gov identifier: NCT03869619.
Keywords: Cohort study, Outcomes, Lymphoma patients, Real life, France
Background
Lymphomas comprise a heterogeneous group of more
than 80 distinct entities classified on the basis of mor-
phological, phenotypic, genotypic, and clinical character-
istics [1]. Their age-adjusted incidence rates worldwide
are more elevated in the most developed countries [2].
In France, they represent two thirds of hematopoietic
cancers with an estimated 28,000 incident cases in 2018
(2000 Hodgkin lymphoma (HL) and 26,000 Non-
hodgkin lymphoma (NHL)) [3]. The time trends in inci-
dence over the last 30 years show an increase for most
of the lymphoma subtypes (e.g. HL, follicular lymphoma
(FL), diffuse large B-cell lymphoma (DLBCL), Marginal
Zone Lymphoma (MZL) or Non-cutaneous mature T-
cell lymphoma) [3]. This increase may be partly ex-
plained by the growing and ageing general population,
as well as a better access to diagnosis and treatment. But
other risk factors are suspected to be involved in the ris-
ing incidence [3]. Epidemiological studies have identified
various factors associated with lymphoma onset, includ-
ing socio-demographic factors, infectious disease status,
family and medical history, lifestyle as well as occupa-
tional exposures (reviewed in Morton et al. [4]). There is
a large etiologic heterogeneity among subtypes, with
shared and distinct factors depending on subtypes, sug-
gesting both subtype-specific and shared underlying
mechanisms.
As for patient care, treatment efficacy greatly varies
depending on histological lymphoma subtypes. Over the
past 15 years, numerous therapeutic innovations have
marked the treatment of lymphomas. For example, over-
all survival of patients with some main subtypes, includ-
ing DLBCL, improved substantially in the last two
decades with the introduction in 2003–2006 of anti-
CD20 monoclonal antibodies in combination with
chemotherapy as a first-line treatment [5, 6]. These in-
novations impacted the survival of patients with
lymphoma, estimated in the general population. In
France, data from population-based cancer registries
(PBCR; FRANCIM network) showed an improvement in
net survival over time clearly observed for DLBCL and
FL (+18% between 1995 and 2010) whereas Hodgkin
lymphoma survival remained stable (although very
favorable) [7]. These encouraging results concerning the
survival of lymphoma were also observed at European
level [8].
Despite considerable improvement of treatment effi-
cacy, our knowledge of factors associated with response
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to treatment or survival is currently limited and mainly
based on factors related to the disease or its impact on
the patient. Indeed, several factors linked to patients’
prognosis (e.g. histological subtype, staging, extra-nodal
involvement, tumor size, high level of serum lactate de-
hydrogenase) and with patients’ characteristics (e.g. age,
performance status) are well known and integrated in
routine clinical care [9, 10]. There are also major devel-
opments in the research of prognostic markers in rela-
tion with lymphoma pathogenesis, but there is currently
no consensus regarding use of these biomarkers for
therapeutic decisions in real-life settings [11, 12]. Several
epidemiological factors (e.g. medical history, lifestyle in-
cluding physical activity, family history, quality of life)
have been explored for patients’ prognosis, but the
results have been rather inconsistent so far [13–24].
Interestingly, a recent publication identified in a retro-
spective analysis an association between occupational
exposure to pesticides and response to treatment
among DLBCL patients [25], but these results would
need to be replicated in larger population-based pro-
spective studies. Finally, several genome-wide associ-
ation studies (GWAS) identified genome wide
significant constitutional single nucleotide polymor-
phisms (SNPs) at risk for lymphoma, but the role of
host genetic background in relation to patient out-
come was less studied [26, 27].
Consequently, few studies have recently addressed the
extent to which factors like socioeconomic status, social
institutional context (i.e. healthcare system), social rela-
tionships, occupational and domestic exposures, individual
behaviours, lifestyle or genetic determinants are associated
with response to lymphoma treatments and patients’ sur-
vival in the general population. Moreover, as the number
of lymphoma survivors is increasing, it raises new ques-
tions at population level about survivorship, including
long-term sequelae of treatments and quality of life.
From a methodological point of view, most of the
knowledge on disease behavior and treatment efficacy
comes from clinical trials. But because of stringent inclu-
sion criteria, most lymphoma patients are not included
in clinical trials, and patients above a certain age, with
comorbidities or already receiving some medications are
usually excluded. Consequently, the generalizability of
findings to the global lymphoma patient population is
limited [28]. Thus, to complement these, researchers
and stakeholders are now interested in evidence from
real-world data (RWD) [29], i.e. data generated during
routine clinical practice obtained outside the context of
randomized clinical trials (RCT) [30]. For lymphoma pa-
tients, RWD may come from a variety of sources such as
cancer registries or institutional databases, but these
sources often provide limited access to clinical informa-
tion, often no information on routine care, no
epidemiological data, no biological samples or no follow-
up data over years after the diagnosis.
In this context, the “REal world dAta in LYmphoma
and Survival in Adults” (REALYSA) study was initiated
in 2018 to fill this gap. The general objective of this
study is to investigate in real life the prognostic value of
epidemiological, clinical and biological factors for pa-
tients with lymphomas in France. Various indicators
(survival, progression-free survival, treatment response
rates and treatment-related toxicities, second cancer and
appearance of new comorbidities) and patient reported
outcomes (PRO) (e.g. quality of life (QoL), social sup-
port) will be estimated. The prognostic impact of clinical
and epidemiological exposure factors at baseline on vari-
ous outcomes will be measured. Access to healthcare
and health behavior (e.g. screening, care consumption,
type of follow-up and medical exams) will be described.
The details of all treatment lines received will be docu-
mented. This study also has complementary biological
objectives with the global aim to foster national and
international research projects in order to identify new
prognostic factors: (i) to create a virtual tumor library;




REALYSA is a real-life observational multicentric cohort
(registered in the French Jardé Law as a research involv-
ing the human person of category 2 (RIPH2): interven-
tional research involving only minimal risks and
constraints). We aim to recruit 6000 patients over 4 to
5 years. The recruitment started in November 2018. The
duration of the study is 9 years (4 to 5 years of recruit-
ment (2018–2023) and between 4 and 9 years of follow-
up, depending on the date of patient recruitment). The
expected end of study is December 2028. Study design is
described in Fig. 1. Patients are treated according to
standard of care and no additional examination is re-
quired for the study, except for blood samples for subse-
quent biological analyses.
Recruiting centers
The recruiting centers meet at least one of these two cri-
teria (see Fig. 2): 1) being an active center of the Lymphoma
Study Association (LYSA) network with a good potential of
patient recruitment and robust research facilities; 2) being
located in a geographical area (i.e. French département)
covered by a population-based cancer registry (PBCR).
LYSA is the French cooperative group on lymphoma, feder-
ating researchers and medical practitioners from more than
80 healthcare centers throughout the country, in order to
promote clinical research on lymphoma as well as improve
prevention, management and treatment of lymphoma
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patients. Regarding registries, the French cancer surveil-
lance system is an opt-out system, so any patient with a
confirmed diagnosis of cancer and living in areas covered
by a population-based cancer registry is automatically regis-
tered without specific patient consent, thus ensuring the ex-
haustivity of cancer incidence registration in these areas.
PBCR are organized in a collaborative network named
FRANCIM [31]. The main objectives of this network are to
coordinate the 14 general cancer registries and 11
specialized cancer registries, to harmonize patient’s registra-
tion and data quality, to provide epidemiological indicators
(incidence, survival, prevalence) and to coordinate epi-
demiological surveillance and research on cancer. PBCR
will be useful to assess and eventually improve representa-
tiveness of the REALYSA cohort. Thirty-five French hospi-
tals/clinics are currently participating to the study,
including 18 (51%) large University Hospitals, 10 (29%)
smaller general hospitals, 4 (11%) cancer centers and 3 (9%)
Fig. 1 Study design of REALYSA
Fig. 2 Recruiting centers in REALYSA study. Complementary information: The figure has been created by our own team with open source R
software (version 4.0.2), using the packages maptools, raster, maps and mapdata
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private healthcare facilities. Other centers may open during
the recruitment phase, if deemed necessary.
Pilot and extension phase
In order to assess the feasibility of the project in a real-
life setting (i.e. standard hospital service), a pilot phase
was conducted in seven initial centers between Novem-
ber 2018 and June 2019. More than 300 patients were
recruited during this timeframe. An evaluation of the
pilot phase was conducted based on this recruitment
[32]. An average of 47 patients per month had been re-
cruited and data at baseline proved to be of high quality
(e.g. 84% completion on average). The biological samples
had been collected for over 80% of the included popula-
tion. The histological distribution was found to reason-
ably match the national one [3]. Similar results were
found for the median age and age distribution within the
various histological subtypes. Regarding the epidemio-
logical questionnaires, over 85% of the quality of life and
social support data had been collected and approxi-
mately 50% of the interview had been performed (a 3-
month delay is given to the centers to perform the inter-
view, explaining this lower percentage at the time of the
cut-off). In addition to this quantitative approach, a
qualitative evaluation was performed through an online
survey and phone calls with Clinical Research Assistants
(CRA) in charge of the study in the recruiting centers. It
showed a satisfactory integration of the program in rou-
tine care, a good compliance with study guidelines and
no major difficulty regarding patient recruitment, data
access or entry, as well as biological sample manage-
ment. This analysis proved that the program was oper-
ational for an extension phase with minor modifications.
For instance, the option to report continuous treatment
(per os) was added in the eCRF, and a few items were
simplified in the questionnaire to streamline the inter-
view. Visual tools were also prepared to help the patient
fill out the questionnaire. These adjustments were ap-
proved by the ethics committee at the end of 2019.
The extension phase was then launched in December
2019, with the opening of nine additional centers. A
third phase of opening started in November 2020, with




Patients meeting all the following criteria are considered
for enrollment in the study:
 Signature of the REALYSA consent form;
 Aged over 18 at the time of inclusion;
 Newly diagnosed with lymphoma in the last 6
months (180 days);
 Lymphoma subtype belonging to at least one of
the 7 histological subtypes: Diffuse large B-cell
lymphoma, Follicular lymphoma, Mantle cell
lymphoma, Marginal zone lymphoma, T-cell
lymphoma, Hodgkin’s lymphoma, Burkitt lymphoma.
Exclusion criteria
Patients meeting any of the following criteria are ex-
cluded from enrollment:
 Anti-lymphoma treatment already received (except
pre-phase therapy: typically, corticosteroids, vincris-
tine, cyclophosphamide and rituximab, alone or in
combination);
 Documented HIV infection.
Details regarding included and excluded lymphoma
subtypes can be found in Additional file 1.
Inclusion procedure
Eligible patients are invited to participate in the study
during a medical consultation with their hematologist.
Patients are given detailed information regarding the
project, including the follow-up modalities. If they agree
to participate, they sign an informed consent form. The
investigators then register the patient directly on the
data capture system through the internet network.
In parallel, the pathological report of each patient in-
cluded in REALYSA is sent to the coordinating center of
the French cancer registries at Bordeaux (see Additional
file 2). These data will be compared with incident cases
collected by registries to analyze the representativeness
of the population included in the REALYSA program.
Data collection and management
Baseline
Collected data at baseline include clinical data on patient
medical history and lymphoma diagnosis, lifelong history
of residences and occupations (these self-administered
questionnaires will gather the complete occupational
history for each job held for at least 6 months as well as
residential history for each place occupied for at least 1
year), as well as professional and domestic exposures,
leisure time activities, lifestyle factors and women’s
health (epidemiological questionnaire during a face-to-
face interview) (see Table 1). Moreover, self-
administered questionnaires assessing QoL and social
support are filled in by the participants. Finally, the G8
questionnaire (i.e. geriatric patient screening test for eld-
erly patients with cancer [33]) is administered by the in-
vestigators to patients over 70 years old. Clinical and
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treatment data are extracted from the patient medical
record and entered in an electronic case report form
(eCRF) through a secure web-based platform (Clinical
Data Management System Ennov®) by the CRA in the
participating centers. Data regarding quality of life, social
support and G8 questionnaire are also entered directly
in the eCRF. Epidemiological and other self-
administered questionnaires are sent to the University of
Bordeaux for centralized data entry in a dedicated epi-
demiological database (Redcap®, 9.5.6 Vanderbilt Univer-
sity) to ensure data homogeneity.
Follow-up
Timepoints for data collection during follow-up are de-
scribed in Table 2. Clinical data, as well as lifestyle
changes, new morbidities, professional situation and
work stress, infertility issues, use of alternative medicine
are collected using data from medical record or via self-
administered questionnaires filled in by the patients.
Follow-up of patients is performed every 6months dur-
ing the first 3 years and annually thereafter until year 9.
Due dates for completing the follow-up are generated
from the diagnosis date (i.e. date of biopsy).
Questionnaires are either mailed by the CRA or given
to the patient during a medical consultation for regular
follow-up. Patients will give back to the CRA the ques-
tionnaires or mail them to the center using a pre-paid
envelope. If questionnaires are not returned by patients
in a timely manner, CRA and their hematologist will
contact the patient by phone to motivate him/her to fill
in and return the questionnaires.
CRA are in charge of follow-up data entry into the
eCRF.
Measurement instruments
Several measurement instruments are used in this
program.
Quality of Life is assessed using the EORTC (European
Organisation for Research and Treatment of Cancer)
QLQ-C30 questionnaire together with three lymphoma-
specific modules [34]:
– For patients with Hodgkin Lymphoma: QLQ-HL27;
– For patients with Non-Hodgkin Lymphoma - High
Grade: QLQ-NHL-HG29;
– For patients with Non-Hodgkin Lymphoma - Low
Grade: QLQ-NHL-LG20.
Five dimensions may be assessed: (i) symptom burden
due to disease and/or treatment; (ii) neuropathy (only
Table 1 Overview of collected data at baseline
Collected data Data source Data entry system Staff member for data
entry
Demographics Patient medical record eCRF CRAa
Care pathway Patient medical record eCRF CRA
Medical history and concomitant
treatments
Patient medical record eCRF CRA
Characteristics at initial diagnosisb Patient medical record eCRF CRA
Lifelong history of residences Auto-questionnaire Epidemiological
database
Data entry operator
Lifelong history of occupations Auto-questionnaire Epidemiological
database
Data entry operator
Medical Historyc Epidemiological questionnaire (interview) Epidemiological
database
Data entry operator
Professional and domestic exposures Epidemiological questionnaire (interview) Epidemiological
database
Data entry operator
Lifestyle Epidemiological questionnaire (interview) Epidemiological
database
Data entry operator
Women health Epidemiological questionnaire (interview) Epidemiological
database
Data entry operator
Quality of life Auto-questionnaire (QLQ-C30 + lymphoma specific
modules)
eCRF CRA
Social support Auto-questionnaire (SSQ6) eCRF CRA




bincluding date, clinical/biological details of the pathological diagnosis, nodal/extra-nodal involvement, exams performed, staging, hematology and biochemistry
laboratory data, serologies
cincluding personal history of infectious diseases, allergies, cancers, chronic diseases, treatments, imaging and family history of hematological malignancies
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for NHL-High Grade); (iii) symptomatic scale for phys-
ical fatigue; (iv) emotional impacts; and (v) worries/fears
about health and functioning.
Social support is measured using the French validated
version of the SSQ6 questionnaire [35, 36]. This ques-
tionnaire measures two dimensions of perceived social
support: (i) the availability of social support; and (ii) the
satisfaction regarding this support.
The G8 geriatric screening tool is used by the investi-
gator during the medical consultation to identify elderly
patients (> 70 years) who could benefit from comprehen-
sive geriatric assessment [33].
Work stress will be estimated using the Siegrist ques-
tionnaire (short version) [37].
Pathology review
We collect date of biopsy, the methods of biopsy (e.g.
excision, core) and the initial pathological report. The
diagnosis of enrolled lymphoma patients is based on the
pathology report and are classified according to World
Health Organization (WHO) criteria [1]. Because a na-
tional pathology review by a panel of hematopathologists
is already organized in France for lymphoma within the
Lymphopath histopathological network, we will cross-
check each new diagnosis with this network of experts
that validate the diagnosis of more than 70% of French
lymphoma cases [38]. For patients also included in LYSA
clinical trials, the centralized diagnosis review performed
for the trial will be cross-checked with the REALYSA
data. In addition, for specific studies on REALYSA data-
base, some extracted cases could be reviewed by expert
hematopathologists.
Project coordination
The project is sponsored by the Hospices Civils de Lyon
(HCL) and coordinated by the LYSA and its academic
clinical research association LYSARC based in Lyon, to-
gether with the Inserm unit EPICENE (public research
unit specialized in cancer epidemiology and environ-
mental exposures) based in Bordeaux. There are two
principal investigators (one professor of hematology
based in Hôpital Lyon Sud and one expert in lymphoma
epidemiology based in the Gironde registry as well as
EPICENE team in Bordeaux), and each principal investi-
gator is responsible for leading its study component (i.e.
clinical component and epidemiological component),
working in close collaboration with the study team.
Table 2 Overview of data collection timepoints during follow-up
Collected data Data source M6 M12 M18 M24 M30 M36 Y4 Y5 Y6 Y7 Y8 Y9
Disease status at last hematology
consultation
Patient medical record x x x x x x x x x x x x
Number of consultations and
imaging exams
Patient medical record x x x x x x x x x x x x
Treatment linesa Patient medical record x x x x x x x x x x x x
Response to treatment Patient medical record x x x x x x x x x x x x
Adverse events Patient medical record x x x x x x x x x x x x
Relapses/progressions/
transformationsb
Patient medical record x x x x x x x x x x x x
New malignancy Patient medical record x x x x x x x x x x x x
New morbidities Auto-questionnaire x x x x x x x x x
Lifestyle Auto-questionnaire x x x x x
Professional situation Auto-questionnaire x x x x x
Work stress Auto-questionnaire (Siegrist questionnaire) x x x x x
Quality of life Auto-questionnaire (QLQ-C30 + lymphoma
specific modules)
x x x x x
Social support Auto-questionnaire (SSQ6) x x x x x x x x x x
Women sexual and reproductive
health
Auto-questionnaire x
Health behaviorsc Auto-questionnaire x x x
Date and cause of death Patient medical record
End of study: reasons for early
termination
Patient medical record
adetailed therapies, start/end dates, dose modality (full/reduced in chemotherapy), amount of Gray if radiotherapy, transplant and other surgeries
bdates, involvement, available documentation, method of evaluation used, staging
cincluding use of alternative medicine, screening behaviors
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The governance is shared between two committees.
The Scientific Committee is a working group of aca-
demic members chosen by LYSA/RC and EPICENE for
their scientific expertise in epidemiology, statistics, clin-
ical medicine or biology. Its main mission is to ensure
the consistency and scientific quality of REALYSA. It is
also in charge of evaluating the relevance and scientific
quality of projects using REALYSA data. Moreover, all
communications and scientific publications of REALYSA
and of projects using REALYSA data are reviewed by the
Scientific Committee. The Steering Committee is com-
posed of members of the LYSA/RC and EPICENE, rep-
resentative of the HCL, representatives of the
investigating centers (principal investigator and repre-
sentatives of DRCI (Department of Clinical Research
and Innovation, i.e. department managing clinical re-
search projects in hospitals)) and representatives of in-
dustrial companies supporting the implementation of
REALYSA. Its main mission is to discuss the progress of
the project implementation and the areas for
improvements.
The routine coordination is ensured by the study
team, composed of the two coordinating investigators,
three project managers, a biostatistician and two data
managers. The study team is in charge of producing and
providing the study documents, ensuring the regulatory
compliance, assisting the recruiting centers, as well as
ensuring data completion and quality. It also coordinates
the submission process of projects using REALYSA data,
including the review by the Scientific Committee.
For each project aiming at analyzing REALYSA data
or samples, there will be a project leader with relevant
expertise. This project leader will submit a project to the
REALYSA Scientific Committee, and if the project is val-
idated, the project leader will work with the study team
to implement the project.
Data quality
Data completion and homogeneity
To ensure the best level of data completion and homo-
geneity, a number of tools have been developed by the
study team and shared with the centers:
– detailed completion guidelines for clinical eCRF and
epidemiological questionnaires;
– Standard Operating Procedures for patient inclusion,
template of excel sheets to plan follow-up timepoints,
visuals for face-to-face interviews (e.g. contraceptive
packaging);
– regular contacts between the project managers and
the CRA: in-person initiation visit (4 h), check-up
calls after the first interviews, CRA meetings (on the
sidelines of the LYSA congress);
– regularly updated Frequently Asked Questions
(FAQ);
– listings of missing data or missing documents and
upcoming follow-up timepoints.
Moreover, a center specific report summarizing the
data of the centers and comparing their data to the
whole cohort population is produced and sent to each
center twice a year. Finally, local investigators are all part
of the Scientific Committee and receive the minutes.
Data validation
A strong data validation system inspired from clinical re-
search standards has been implemented and is regularly
running, with different levels of data checking. First, the
electronic data entry system contains automatic checks
performed at regular intervals for data completeness and
consistency. Second, a scientific review is conducted by
the study team to guarantee scientific coherence of data.
Last, a medical review is performed by center investiga-
tors to ensure overall clinical data coherence of major
endpoints (e.g. treatment plan, staging, response to treat-
ment, events during the follow-up like progression, re-
lapse or death). In case of incoherence and when
deemed necessary, queries are generated and sent to the
centers. Corrections are edited in the eCRF and tracked
in the audit trail. At regular intervals, the overall com-
pleteness and quality of the data is assessed.
Epidemiological data are systematically checked for ab-
errant or missing data. If there is extensive missing data
or if clarification is needed, the CRA in charge of the
interview is contacted.
Biological samples
For the first 2500 patients included in REALYSA, blood
samples will be collected at baseline (before any treat-
ment), during first-line treatment, at end of first-line
treatment and at relapse. Additional blood samples are
also collected for patients with anaplastic lymphoma kin-
ase positive (ALK+) anaplastic large cell lymphoma
(ALCL), for specific analyses on antibodies and nucleo-
phosmin (NPM) transcript. Details are presented in
Table 3. In case of premature first line treatment discon-
tinuation (before cycle 3), the samples will be drawn at
the time of treatment discontinuation.
Virtual tumor biobank
The standard management of patients for their path-
ology includes taking tumor biopsies to establish the
diagnosis. The remaining tumoral material (biopsy in-
cluded in paraffin or frozen) will be requalified for re-
search and stored by the centers. This material could be
requested for specific projects in the future.
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Statistical analysis
Sample size calculation
No sample size calculation is strictly required for cohort
studies but was needed for planning and funding per-
spectives. We have therefore used a pragmatic approach,
based on one of the objectives of the study, which is to
be able to detect an association between the exposure of
interest and the clinical outcome of interest (e.g. re-
sponse to treatment, progression-free survival, overall
survival – see section on clinical outcomes) for a given
lymphoma subtype. First, using lymphoma incidence
rates [3, 39] in the geographical study zone, we esti-
mated the number of new lymphoma cases that could be
recruited in REALYSA over a 4-year recruitment period.
Second, we calculated the hazards ratio (HR) that this
study would be able to detect as a function of the num-
ber of events, which can be then back transformed to a
number of patients of a given lymphoma subtype.
Firstly, based on the initially planned recruiting cen-
ters, we would expect 2796 new lymphoma cases yearly,
so a total of 11,183 new cases during the 4 years of in-
clusion (unpublished data coming from an extraction of
registry data). Considering a participation rate of 70%
and an improving dynamic recruitment rate (40% during
the 1st year, 75% the 2nd year, and 100% on the last 2
years), the number of cases that could be recruited in
REALYSA is around 6000 patients (exactly 6165 pa-
tients, distributed as follows: 911 patients with HL, 2123
patients with DLBCL, 1294 patients with follicular
lymphoma (FL), 344 patients with mantle cell lymphoma
(MCL), 88 patients with Burkitt lymphoma, 958 patients
with MZL and 447 patients with NHL-T).
Secondly, we calculated the detectable HR assuming a
binary exposure of interest (say “present” vs “absent”).
We relied on the proportional hazard model to describe
the association between the exposure and the mortality
hazard, with a 2-sided test at α = 0.05 (type 1 error rate)
and a desired 80% power (i.e. 1 minus the type 2 error
rate). With a pre-specified value for the prevalence of
the exposure in our sample, we can obtain the detectable
HR as a function of the number of events [40]. In order
to get an absolute measure of the difference between
groups (as opposed to the HR, which is a relative meas-
ure), one could use the link between HR and survival.
This would allow to express the difference between the
survival of the exposed, S1(t), and the unexposed S0(t) as:
S1(t) = S0(t)
HR.
We investigated scenarii with 3 levels of prevalence for
the exposure: 10, 20 and 30%. The results are shown in
Fig. 3 with the detectable HR according to the number
of events. We would need to observe 530 events to be
able to detect a HR of 1.5 with a type I error rate of
0.05, a power of 0.8 and an exposure prevalence of 10%.
Therefore, if we assume that the proportion of events
among the cases is approximately 30% (as observed for
example for DLBCL for 1-year survival in France [7],
and assuming no lost-to-follow up), then we need to ob-
serve 1767 patients with DLBCL (530/0.3). This HR of
1.5 in the context of DLBCL would then correspond to a
1-year survival of 70% in the unexposed group vs 59% in
the exposed group. Despite the fact that this approach
for sample size calculation relies on many assumptions,
it has the advantage of being general and versatile to our
different settings (i.e. according to lymphoma subtype
and clinical outome of interest).
Consequently, the sample size was set at 6000 patients,
as a good balance between feasibility and statistical
power, at least for most common subtypes (i.e. DLBCL,
FL and HL).
Representativeness analysis
One of the objectives of this program is to have a satis-
factory representativeness of the included population as
compared to patients diagnosed with lymphoma in the
general population, thus allowing generalization of the
results. Twice a year and for each sex-lymphoma sub-
type combination, we compare age distribution of inci-
dent cases between the national incidence estimates
based on FRANCIM data [3] and the REALYSA cohort
to monitor the evolution of representativeness. We also
compare the distribution of the lymphoma subtypes be-
tween the national estimates and REALYSA. Compari-
son of the main confounders’ distributions (i.e. sex, age,
lymphoma subtype, stage, performance status) is also











Baselinea x x x x x




First relapse x x
abefore any treatment
bNPM Nucleophosmine
cALK+ ALCL anaplastic lymphoma kinase positive anaplastic large cell lymphoma
dAb Antibodies
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done bi-annually between REALYSA centers, in order to
identify potential bias in patients’ recruitment in specific
centers. Moreover, two pilot départements (Gironde and
Isère) covered by cancer registries have been chosen to
cover an increased proportion of the population by
opening 3 to 4 centers in the département. Specific ana-
lyses will be performed in these départements to conduct
a fine-tuned analysis of the representativeness, which
will be very helpful to adjust for the global cohort if ne-
cessary, using particular statistical techniques [41].
Clinical outcomes
The following clinical measures will be recorded at dif-
ferent timepoints: response to treatment, progression-
free survival (PFS), event-free survival (EFS), time to
next anti-lymphoma treatment (TTNLT), overall sur-
vival (OS). Other quantities of interest, such as the net
survival, survival after progression, transformations, on-
set of second cancers will also be studied.
Generalities on the statistical methods for basic description
of the association between the variables and time-to-event
outcomes
Continuous variables will be summarized in tables dis-
playing sample size, mean, standard deviation, median,
and range; quartiles will also be presented when consid-
ered relevant. Categorical variables will be described in
counts and percentages, including a specific category for
missing data. Time to events will be described using
Kaplan-Meier method, and survival probabilities (with
the corresponding curves) will be provided with their
95% Confidence Interval (CI). For (semi-) competing
risks setting (i.e. dealing with multiple event types),
cumulative incidence functions will be our measure of
interest.
Association between a categorical baseline prognos-
tic factor and the time to event will be assessed by a
two-sided log-rank test and quantified with a hazard
ratio (HR) with 95% CI as estimated from a Cox
model including only this variable as predictor. The
continuous baseline prognostic factors will be catego-
rized using the quantiles of their observed distribution
and we will apply the same strategy as the categorical
prognostic factors. Additionally, for the continuous
factors, we will use their original version in a survival
model (e.g. Cox or flexible parametric model) to esti-
mate the (eventually time-dependent) HR associated
with a 1-unit increase of the factor. Multivariable sur-
vival models will also be used for estimating condi-
tional HRs for the main clinical and epidemiological
factors. Time-updated prognostic factors will be ana-
lyzed using extensions of the survival models
aforementioned.
Despite all the efforts made for representativeness, the
cohort might end up not being representative of the
French general population of lymphoma patients. In that
case, statistical techniques such as covariate adjustment
methods [42] or methods based on the Inverse probabil-
ity weighting (IPW) technique [43] could be imple-
mented to correct for this bias [41, 44]. In that regard,
the REALYSA setting in which the recruiting centers are
located in départements also covered by PBCR will be
very useful.
Fig. 3 Detectable hazard ratio according to the number of events for different levels of exposure prevalence
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Main prognostic epidemiological factors
For each topic, relevant indicators of exposure will be
defined. As an example, the following topics will be ana-
lyzed to study their association with clinical outcomes
(non-exhaustive list): tobacco smoking, alcohol con-
sumption, socio-professional categories, medical history,
medical family history of cancer, domestic exposures,
occupational exposures. Additionally, for each analysis,
potential confounding factors will be considered on a
case-by-case basis, as they may influence the prognostic
of lymphoma in the population, such as the international
prognostic indexes, socio-economic status, lifestyle
habits and treatments. Other potential confounding fac-
tors such as the population density, the presence of pol-
luting industries, urban or rural status of the place of
residence will be used whenever necessary. In case of a
substantial amount of missing data in one or more po-
tential confounders, we will rely on multiple imputation
techniques.
Ethics
The study is performed according to the declaration of
Helsinki, and national laws and regulations for RIPH2
studies. The REALYSA study was approved by a French
ethics committee (Comité de Protection des Personnes
Ouest II - file number: 2018/46) and by the National
Commission for data protection and freedom of infor-
mation (CNIL - decision number: DR-2018-238). Writ-
ten informed consent is obtained from patients before
any data collection. A specific signed consent form is
also obtained from each patient willing to participate in
genetic studies that may be conducted on blood samples.
Patients are free to refuse to participate or to withdraw
from the study at any time. Collected data are anonym-
ous and secure data management systems are used. Any
substantial change of the protocol (e.g. number of cen-
ters, number of collected blood samples) will be vali-
dated by the ethics committee before implementation.
Discussion
This cohort will include around 6000 patients with clin-
ical, epidemiological and biological data. This initiative
constitutes a great opportunity to set up and emulate col-
laborative research projects on a wide range of topics, with
the overall aim of improving knowledge on lymphoma pa-
tients’ outcomes in real-life setting.
France is a particularly appropriate country to set up
such study due to a global organization in diagnosis,
clinical research and epidemiological surveillance of
lymphoma patients. The LYSA is a very active and well-
structured organization which brings together profes-
sionals specialized in the field of lymphoma across the
country and plays a leading role in coordinating cutting-
edge research projects on lymphoma. REALYSA also
takes advantage of the presence of the national Lympho-
path network to improve the quality of diagnosis of in-
cluded patients [38]. As the LYSA is a group specialized
in clinical trials in lymphoma, there is also a systematic
diagnostic review for patients included in clinical trials
by the hematopathologists of LYSA Pathology commit-
tee. For these reasons, we did not choose to centralize
all tissue blocks as has been done in other lymphoma
cohorts (e.g. LEO – SPORE [45]), but we created a vir-
tual tumor bank for the accessibility of tumor tissues for
specific studies. Finally, the close collaboration between
REALYSA and FRANCIM offers an innovative oppor-
tunity for a formal evaluation of the representativeness
of patients included in this prospective cohort by map-
ping data obtained from REALYSA inclusion and those
recorded in registries. To the best of our knowledge, this
type of prospective collaboration between clinical cen-
ters and registries is unique at a national level.
Other prospective cohorts are currently implemented
such as the Haematological Malignancy Research Net-
work (HMRN). In this population-based cohort, all
hematological malignancies were prospectively included
since 2004 in a specific geographical area of United
Kingdom [46, 47]. The Lymphoma Specialized Program
of Research Excellence (SPORE) Molecular Epidemi-
ology Resource (MER) cohort enrolled prospectively pa-
tients from Mayo Clinic (Rochester, Minnesota) and the
University of Iowa (Iowa City, Iowa) since 2002 [45]. In-
vestigators extended this program in 2015 to eight US
centers as part of the Lymphoma Epidemiology of Out-
come (LEO) program (NCT02736357). The objectives of
REALYSA cohort are close to the ones of these pro-
grams but we expect to have a cohort with as much as
possible a national coverage with a control of the repre-
sentativeness thanks to data from registries (see Fig. 2).
Although clinical trials remain the gold standard for
the evaluation of new treatment options, a majority of
lymphoma patients are currently treated outside clinical
trials. In addition, large prospective phase III trials are
now less frequent with the development of therapeutic
trials targeting specific populations, for instance with a
particular lymphoma pathogenesis. With comprehensive
clinical/biological data collections, we will be able to de-
termine the efficacy and toxicities of some treatment op-
tions performed in daily practice that avoid the problem
of patient selection in clinical trials. For instance, we ob-
served that the median age of DLBCL in general popula-
tion is more than 70 years old [48], but was estimated
near 60 years old in clinical trials or in clinic-based ob-
servational cohort from tertiary hospitals [49]. Compari-
son of patients with mantle cell lymphoma (MCL)
included in clinical trials or registered in cancer regis-
tries showed that patients from clinical trials were youn-
ger and had less advanced stage; there was also an
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excessive mortality mainly in elderly MCL patients from
registries confirming patient selection bias in clinical tri-
als [50]. In this setting, we will also be able to prospect-
ively validate clinical prognostic scores (e.g. FLIPI, MIPI)
among real-life patients. The validation of clinical trial
results in general population after approval is also a
major challenge for new targeted therapies in lymphoma
such as Chimeric Antigen Receptors (CAR) T-cells, new
monoclonal antibodies or tyrosine kinase inhibitors re-
garding specificities of their uses, specific adverse effects
and cost. For instance, in a recent study of the HMRN
network, the impact of novel therapies in real-life set-
tings for outcome of MCL patients was well documented
[51]. In this context, a prospective cohort such as
REALYSA will offer a better evaluation of new therapeutic
options than retrospective studies with possibility of
health-economic studies. For these new therapeutic op-
tions, a comparison between REALYSA patients included
in clinical trials vs REALYSA patients not included in clin-
ical trials will also be possible, as we collect information
about clinical trial participation. The utility of RWD for
the detection of rare or late toxicities is now well recog-
nized [52]. For instance, after the publication of cardiac
surveillance guidelines mostly based on RWD, the cardiac
surveillance rate of lymphoma patients treated by
anthracycline-based therapy seemed to improve [53]. The
analysis of prospective RWD collections has informed
clinical practice, in particular for rare lymphoma subtypes
and for clinical situations for which designing clinical tri-
als remains difficult: for instance, the modality of DLBCL
and HL patient surveillance after first line therapy was
modified by data coming from RWD showing the contro-
versial use of routine CT-scan for the detection of relapses
[54–56]; similarly, use of RWD contributed to the defin-
ition of new survival endpoints such as EFS24 in DLBCL
or the comparison of patient life expectancy with general
population [57–59].
Recently, there is a major effort to aggregate biological
collections from several institutions or among consor-
tium with samples coming from patients mostly treated
in real-life setting. For instance, three major studies from
a group of institutions investigated the relation between
genome/exome sequencing with the prognosis of
DLBCL patients [11, 60, 61]. In REALYSA, we will bank
an important number of biological specimens, allowing
ambitious biological and genetic studies to identify new
biological markers from tumors but also from the host
with germline DNA analyses. Interestingly, with the col-
lection of clinical, biological and epidemiological data,
we will be able to analyze the challenging question of
the interaction between environmental exposure and
tumor biology [62], as well as extend our previous works
on the relation between inherent genetic variations ana-
lyzed by GWAS and prognosis [27].
The longitudinal evaluation of patients during follow-up
is a major objective in our cohort. The collection of data
regarding professional situation, reproductive health,
health behaviors, appearance of new morbidities and evo-
lution of QoL will be of great utility to describe and
analyze specific challenges of daily living for lymphoma
survivors in the general population. In this context, recent
works in advanced-stage lung cancer showed that the self-
reported symptoms during follow-up using a web-based
application improved overall survival due to an early de-
tection of relapse [63].
Several weaknesses may be identified in this study. First,
unlike other cohorts (e.g. HMRN), not all lymphoid malig-
nancies are included in REALYSA. We elect not to in-
clude patients with chronic lymphocytic leukemia (CLL)/
lymphocytic lymphoma, primary central nervous system
(CNS) lymphoma and post-transplanted lymphoma as
there are other national networks for these lymphoid ma-
lignancies and their managements are very distinct from
other NHL subtypes. Similarly, primary cutaneous T-cell
lymphoma that are mainly diagnosed, treated and
followed by dermatologists specialized in this disease are
not included. Second, depending on the subtypes, the stat-
istical power may be limited in some cases. Indeed, the
comprehensive occupational and domestic exposure ques-
tionnaire, associated with clinical data, will help in under-
standing the role of environmental conditions (including
socio-economic status, social institutional context, social
relationships, environmental exposures, individual behav-
iors, lifestyle) on lymphoma prognosis. Previous studies
suggested the potential prognostic impacts of some envir-
onmental exposures on lymphoma patient outcome [25,
62]. The major issue of these studies is to have sufficient
statistical power to prove an association depending on ex-
posure prevalence, the sample size of the lymphoma sub-
type and the number of events. We think that for the
most frequent lymphoma subtypes, such as DLBCL, FL
and HL, the power would be satisfactory to detect some
environmental conditions as prognostic factors. We
recognize that infrequent lymphoma subtypes or for low
prevalence exposures, results will be considered as ex-
ploratory and will need further replications for instance
through international collaborations.
Finally, there are three major challenges in this study.
First, we will have to pay strong attention to recruitment
dynamics and patient characteristics to avoid recruit-
ment biases and to have a population as representative
of the general population of lymphoma patients as pos-
sible. Strong guidelines are given to centers in order to
recruit all patients meeting the inclusion criteria, with-
out any distinction on age, general condition or clinical
prognosis. Moreover, smaller and non-University centers
were opened during the extension phase in order to cap-
ture a larger population of patients, including those
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treated outside University Hospitals. Interim analyses
will be conducted in order to compare participants’
characteristics with registries data. Nevertheless, even if
the cohort is not representative of the whole French popu-
lation of lymphoma patients, we strongly believe that
building such cohort will be of use for many research
works despite the lack of representativeness, as long as the
“scientific inference is still valid” [64, 65]. The second
challenge is the retention of patients in the cohort. Pro-
spective follow-up is tied to the diagnosis date, in order to
follow clinical management (e.g. annual follow-up from
diagnosis), thus facilitating patient engagement. Newslet-
ters with information on the study and projects will be
sent to patients, in order to create a sense of belonging to
the study. A dedicated webpage has also been created and
updated with information on study and projects. Lastly,
we aim to involve patients as partners of this research in
order to facilitate communication and feedbacks between
the research team and the patients included in the cohort
and eventually minimize the attrition rate. Finally, as for
all real-world studies, data completeness remains a major
challenge. However, this study being conducted by investi-
gators and CRA belonging to the hematological depart-
ments, we trust that this will maximize our capacity to
recover satisfactory data.
This cohort is a perfect framework for multidisciplin-
ary projects, as well as national and international collab-
orations. The close partnership with the LEO study team
[45] and InterLymph consortium [66] will facilitate
international projects and comparative analysis. For
some rare subtypes with low numbers (e.g. Burkitt
lymphoma), data could be pooled with other inter-
national cohorts to obtain relevant and robust results for
these rare lymphomas [67], as it was already and suc-
cessfully performed in a large pooling initiative studying
risk factors for 11 NHL subtypes on behalf of Inter-
Lymph consortium [68]. Proposals for collaborative re-
search projects from all disciplines will be considered by
the study team.
Trial status: recruiting.
Protocol version 2.0, date: 09-01-2020.
Start recruitment: 11-14-2018.
Approximate date recruitment completion: 11-14-2023.
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